Delving into the Latest Updates on Chlorpromazine Phenolphthalinate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Chlorpromazine phenolphthalinate (JAN), Wintermin, ウインタミン

Target

ADRA2 x D2 receptor x Histamine receptor

Action

antagonists

Mechanism

ADRA2 antagonists(Adrenergic receptors alpha-2 antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists), Histamine receptor antagonists

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

ManiaNeurotic DisordersNausea and vomiting+ [8]

Inactive Indication-

Originator Organization

Shionogi & Co., Ltd.

Active Organization

Shionogi & Co., Ltd.

Kyowa Pharmaceutical Industry Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (01 Jan 1977),

AnesthesiaAnxiety DisordersBipolar Disorder+ [5]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H19ClN2S

InChIKeyZPEIMTDSQAKGNT-UHFFFAOYSA-N

CAS Registry50-53-3

View All Structures (2)

The primary purpose of this study is to evaluate the overall effect of caregivers receiving a study-provided caregiver psycho-education and skills training program on the number of treatment failures (psychiatric hospitalization, psychiatric emergency room (ER) visit, crisis center visit, mobile crisis unit intervention, arrest/incarceration, and suicide or suicide attempt) in patients under their care during a 12 month period.

Start Date24 Jul 2015

Sponsor / Collaborator

Janssen Scientific Affairs LLC

100 Clinical Results associated with Chlorpromazine Phenolphthalinate

Login to view more data

100 Translational Medicine associated with Chlorpromazine Phenolphthalinate

Login to view more data

100 Patents (Medical) associated with Chlorpromazine Phenolphthalinate

Login to view more data

18,901

Literatures (Medical) associated with Chlorpromazine Phenolphthalinate

01 Jun 2025·Biomaterials

Transduction enhancing EF-C peptide nanofibrils are endocytosed by macropinocytosis and subsequently degraded

Article

Author: Read, Clarissa ; Glocker, Bernhard ; Schütz, Desiree ; Rauch-Wirth, Lena ; Münch, Jan ; Walther, Paul ; Müller, Janis A ; Groß, Rüdiger ; Rode, Sascha

Retroviral gene transfer is the preferred method for stable, long-term integration of genetic material into cellular genomes, commonly used to generate chimeric antigen receptor (CAR)-T cells designed to target tumor antigens. However, the efficiency of retroviral gene transfer is often limited by low transduction rates due to low vector titers and electrostatic repulsion between viral particles and cellular membranes. To overcome these limitations, peptide nanofibrils (PNFs) can be applied as transduction enhancers. Among these, PNFs derived from the 12-mer peptide EF-C are well-investigated and commercially available. EF-C PNFs enhance transduction by forming EF-C PNFs/virus complexes that overcome electrostatic repulsion through their polycationic surface and interaction with cellular protrusions. However, the safe application of PNFs as transduction enhancers in gene therapeutic applications requires a fundamental understanding of their transduction-enhancing mechanisms, uptake, and degradation. In this study, we demonstrate that EF-C PNFs induce plasma membrane invaginations, increasing the membrane surface for viral attachment and reducing the distance to the nuclear membrane, thereby facilitating viral entry and transport to the nucleus. Furthermore, we identified macropinocytosis as the main entry pathway for EF-C PNFs and their subsequent degradation by lysosomal peptidases. The lysosomal degradation of EF-C PNFs prevents their accumulation as amyloid deposits, mitigating potential side effects and supporting their safe use in clinical applications.

03 May 2025·Analytical Letters

Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)

Author: Xin, Lina ; Xia, Ning ; Li, Minglu ; Chen, Yun ; Wang, Li ; Liang, Feiyan

The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.

01 May 2025·Biomaterials

Bioactive phosphorus dendrimers deliver protein/drug to tackle osteoarthritis via cooperative macrophage reprogramming

Article

Author: Mignani, Serge ; Liang, Jiajia ; Ma, Jie ; Majoral, Jean-Pierre ; Laurent, Regis ; Sun, Huxiao ; Shen, Mingwu ; Shi, Xiangyang ; Zou, Yu ; Tang, Guo ; Zhan, Mengsi

Reprogramming imbalanced synovial macrophages and shaping an immune microenvironment conducive to bone and cartilage growth is crucial for efficient tackling of osteoarthritis (OA). Herein, we present a co-delivery nanosystem based on generation 2 (G2) hydroxyl-terminated bioactive phosphorus dendrimers (G2-OH₂₄) that were loaded with both catalase (CAT) and quercetin (Que). The created G2-OH₂₄/CAT@Que complexes exhibit a uniformly distributed spherical morphology with a size of 138.8 nm, possess robust stability, and induce macrophage reprogramming toward anti-inflammatory M2 phenotype polarization and antioxidation through cooperative CAT-catalyzed oxygen generation, Que-mediated mitochondrial homeostasis restoration, and inherent immunomodulatory activity of dendrimer. Such macrophage reprogramming leads to chondrocyte apoptosis inhibition and osteogenic differentiation of bone mesenchymal stem cells. Administration of G2-OH₂₄/CAT@Que to an OA mouse model results in attenuation of pathological features such as cartilage degeneration, bone erosion, and synovitis through oxidative stress alleviation and inflammatory factor downregulation in inflamed joints. Excitingly, the G2-OH₂₄/CAT@Que also polarized macrophages in adherent effusion monocytes (AEMs) extracted from joint cavity effusions of OA patients to M2 phenotype and downregulated reactive oxygen species levels in AEMs. This study suggests a promising nanomedicine formulation of phosphorus dendrimer-based co-delivery system to effectively tackle OA through the benefits of full-active ingredients of dendrimer, drug, and protein.

100 Deals associated with Chlorpromazine Phenolphthalinate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D04034	Chlorpromazine Phenolphthalinate	N05AA01	DB00477

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Mania	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	07 Aug 1997
Neurotic Disorders	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	07 Aug 1997
Nausea and vomiting	Japan	Kyowa Pharmaceutical Industry Co., Ltd.	07 Jul 1977
Anesthesia	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Anxiety Disorders	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Bipolar Disorder	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Depressive Disorder	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Nausea	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Schizophrenia	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Sedation	Japan	Shionogi & Co., Ltd.	01 Jan 1977
Seizures	Japan	Shionogi & Co., Ltd.	01 Jan 1977

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAO2014	Not Applicable	Glaucoma	109	Retrobulbar Chlorpromazine Injection	(amrymtmzbl) = eowlygutve itypvczvky (pxorperfcf )	Positive	19 Oct 2014
ARVO2009	Not Applicable	Pain	17	Chlorpromazine retrobulbar injection	(uetwvkipxo) = 1 patient after one month ovddotfwdu (ciommakuxu ) View more	Positive	01 Apr 2009